These data are in line with a previous report using a preclinical breast cancer model.18 In addition, we observed a slight reduction in infiltrating CD8+ and CD4+ T cells upon ruxolitinib treatment, but an increase in CD4+IL17A+ Th17 cells as well as CD4+Foxp3+ regulatory T cells (Fig. 4d). This evidence concerns the gene IL17A and breast carcinoma.